OA10198A - Stable copper(i) complexes and methods related thereto - Google Patents

Stable copper(i) complexes and methods related thereto Download PDF

Info

Publication number
OA10198A
OA10198A OA60750A OA60750A OA10198A OA 10198 A OA10198 A OA 10198A OA 60750 A OA60750 A OA 60750A OA 60750 A OA60750 A OA 60750A OA 10198 A OA10198 A OA 10198A
Authority
OA
OAPI
Prior art keywords
copper
complex
complexes
stable
bcds
Prior art date
Application number
OA60750A
Other languages
English (en)
Inventor
Alexander J Pallenberg
Andrew Branca
Thomas M Marschner
Leonard M Patt
Original Assignee
Procyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procyte Corp filed Critical Procyte Corp
Publication of OA10198A publication Critical patent/OA10198A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA60750A 1993-06-02 1995-12-01 Stable copper(i) complexes and methods related thereto OA10198A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7144093A 1993-06-02 1993-06-02

Publications (1)

Publication Number Publication Date
OA10198A true OA10198A (en) 1996-12-18

Family

ID=22101339

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60750A OA10198A (en) 1993-06-02 1995-12-01 Stable copper(i) complexes and methods related thereto

Country Status (8)

Country Link
EP (1) EP0701439A1 (fr)
JP (1) JPH08511006A (fr)
AU (1) AU7051794A (fr)
CA (1) CA2163640A1 (fr)
OA (1) OA10198A (fr)
TW (1) TW239077B (fr)
WO (1) WO1994027594A2 (fr)
ZA (1) ZA943857B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562854B2 (en) 1994-12-14 2003-05-13 Axys Pharmaceuticals, Inc. Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
AU6274896A (en) * 1995-06-06 1996-12-24 Procyte Corporation Stable copper(i) complexes as active therapeutic substances
US5637311A (en) * 1995-06-29 1997-06-10 Procyte Corporation Zinc(II) complexes and methods related thereto
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US6150379A (en) * 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
WO2005115379A2 (fr) * 2004-05-24 2005-12-08 New York University Methode de traitement ou de prevention d'effets pathologiques d'augmentations aigues de l'hyperglycemie et/ou d'augmentations aigues de flux d'acides gras libres
NZ565003A (en) * 2005-06-20 2011-11-25 Dynamiclear Pty Ltd Composition for treating skin lesions
KR20110054035A (ko) * 2008-09-03 2011-05-24 가부시키가이샤 엔비씨 메슈테크 항바이러스제
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
TWI580787B (zh) * 2012-12-28 2017-05-01 簡宏堅 重組蛋白質、含有該重組蛋白質之醫藥組成物及該重組蛋白質之製備方法
WO2019055490A1 (fr) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University Conditionnement de tissu irradié pour rétention de greffe de graisse
EP3810144A4 (fr) * 2018-06-04 2022-08-17 Chemistryrx Compositions topiques pour stimuler la pousse des cheveux

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760051A (en) * 1985-01-24 1988-07-26 Pickart Loren R Use of GHL-Cu as a wound-healing and anti-inflammatory agent
JPS6259213A (ja) * 1985-09-10 1987-03-14 Eisai Co Ltd ス−パ−オキサイド除去剤

Also Published As

Publication number Publication date
TW239077B (fr) 1995-01-21
ZA943857B (en) 1995-02-01
WO1994027594A2 (fr) 1994-12-08
CA2163640A1 (fr) 1994-12-08
JPH08511006A (ja) 1996-11-19
EP0701439A1 (fr) 1996-03-20
AU7051794A (en) 1994-12-20
WO1994027594A3 (fr) 1995-04-27

Similar Documents

Publication Publication Date Title
Balzarini et al. 9-(2-Phosphonylmethoxyethyl) adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys
OA10198A (en) Stable copper(i) complexes and methods related thereto
De Clercq The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
Alizadeh et al. Antiviral activities of pyridine fused and pyridine containing heterocycles, a review (from 2000 to 2020)
Touyz et al. Reactive oxygen species in vascular biology: implications in hypertension
US9809616B2 (en) Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer
Meier et al. cyclo Sal-Pronucleotides of 2 ‘-Fluoro-ara-and 2 ‘-Fluoro-ribo-2 ‘, 3 ‘-dideoxyadenosine as a Strategy to Bypass a Metabolic Blockade
Sharma et al. Hypolipidemic, anti-inflammatory, and antineoplastic activity and cytotoxicity of flavonolignans isolated from Hydnocarpus wightiana seeds
MXPA01001893A (es) Derivados de quinazolina.
AU4368799A (en) Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
JP2007532665A (ja) Ｈｉｖインテグラーゼ阻害剤化合物のホスホネート類似物
US5637311A (en) Zinc(II) complexes and methods related thereto
Al-Jafari et al. Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: Phenserine
US6339073B1 (en) Uses of nicotinamide adenine dinucleotide and its derivatives for treatment of malignant and infectious diseases
Sato et al. Evidence of direct generation of oxygen free radicals from heterocyclic amines by NADPH/cytochrome P‐450 reductase in vitro
WO1996039144A1 (fr) Complexes cuivreux stables utilises comme substances a activite therapeutique
Saraswathi et al. Inhibition of glycolysis and respiration of sarcoma-180 cells by echitamine chloride
Sayre et al. Dopaminergic neurotoxicity in vivo and inhibition of mitochondrial respiration in vitro by possible endogenous pyridinium‐like substances
Legrand-Poels et al. HIV-1 promoter activation following an oxidative stress mediated by singlet oxygen
Hampton et al. Evidence for the conformation of enzyme-bound adenosine 5'-phosphate. Substrate and inhibitor properties of 8, 5'-cycloadenosine 5'-phosphate with adenylate kinase, adenylate aminohydrolase, adenylosuccinate lyase, and 5'-nucleotidase
CHATTOPADHYAYA The chemical synthesis and antiviral properties of an acyclovir-phospholipid conjugate
Zheng et al. UNC5293, a potent, orally available and highly MERTK-selective inhibitor
Hamon et al. Effect of antineoplastic and cytotoxic Mannich bases derived from conjugated styryl ketones on mitochondrial respiration in rat liver cells
Rosowsky et al. Synthesis and in vitro activity of long-chain 5 ‘-O-[(Alkoxycarbonyl) phosphinyl]-3 ‘-azido-3 ‘-deoxythymidines against wild-type and AZT-and foscarnet-resistant strains of HIV-1
Tedde et al. Effects of 2′-deoxycoformycin infusion on mouse adenosine deaminase